Congress’ New Drug Safety Priority: FDA’s Authority Over Compounders
This article was originally published in RPM Report
The meningitis outbreak caused by contaminated injectable steroids from a Massachusetts pharmacy is prompting lawmakers to pursue legislation that would clarify FDA’s authority over compounders. The challenge for FDA Commissioner Hamburg is convincing Congress to act, but not deliver an unfunded mandate. One thing is clear: it won’t be a quiet start to 2013 in biopharma legislation.
You may also be interested in...
Health and Human Services watchdog will examine Medicare Part B claims policies and hospital practices related to compounding.
This has been a big year for health-systems pharmacists – and their influence on legislation looks like it will continue to grow.
The Makena controversy is moving to court, and likely to a very unhappy ending for KV Pharma. But FDA’s decidedly unusual communications about compounding in the midst of that controversy may have longer term implications.